Featured Research

from universities, journals, and other organizations

Fatal Copper Disorder Can Now Be Detected At Birth

Date:
February 8, 2008
Source:
NIH/National Institute of Child Health and Human Development
Summary:
A new test could greatly extend the survival of infants with Menkes disease, a rare, otherwise fatal disorder of copper metabolism. The test allows for early diagnosis of the condition, when the chance for successful treatment is greatest.

A test developed by NIH scientists could greatly extend the survival of infants with Menkes disease, a rare, otherwise fatal disorder of copper metabolism. The test allows for early diagnosis of the condition, when the chance for successful treatment is greatest.

Untreated, Menkes disease results in irreparable harm to the brain and nervous system. Treatment consists of injections with a copper-containing drug. Children with Menkes disease typically die during the first decade of life. Previously, there was no blood test for early detection of Menkes disease.

"The study represents an important advance in the diagnosis and treatment of a rare but devastating genetic disorder," said Duane Alexander, M.D., Director of NIH's National Institute of Child Health and Human Development (NICHD), the lead NIH institute that conducted the study. "The laboratory techniques the researchers used to detect Menkes disease eventually may provide the basis for a newborn screening test to identify children with Menkes at birth, so they have the greatest chance to benefit from treatment."

The study was a collaboration between researchers in the NICHD, the National Institute of Neurological Disorders and Stroke (NINDS), and the NIH Clinical Center. The NINDS researchers contributed expertise in testing for nervous system chemicals known as catecholamines. Catecholamine levels are determined by a copper-dependent enzyme and for this reason are abnormal in Menkes disease infants.

Menkes disease occurs in about one in 100,000 newborns and is caused by a defect in a gene that regulates copper levels in the body, explained Stephen G. Kaler, M.D., Clinical Director of the NICHD and lead author of the study. This defect, in the gene designated ATP7A, causes abnormally low levels of copper in the brain and liver as well as excessive amounts of copper in the kidneys and intestines. Copper, although only needed in trace amounts, is an essential nutrient that plays a critical role in brain development, he said.

Infants with Menkes disease usually appear normal at birth but start to show developmental delays at 6 to 8 weeks. Affected children may experience seizures and below normal body temperature. Children with Menkes disease also develop distinctive kinky hair, which is steel-colored or colorless and is easily rubbed off the skull.

Dr. Kaler explained that copper is needed for the production of myelin, an insulating material that surrounds certain types of brain and nerve cells. The deposition of myelin around brain and nerve cells is nearly completed by age 2, so the disorder can potentially be treated if copper replacement therapy is started soon after birth. Symptoms of Menkes disease do not usually develop until 2 to 3 months of age, but by that time, the copper deficiency has already caused significant brain damage which treatment seems unable to reverse, Dr. Kaler said.

The defective gene in Menkes disease is located on the X chromosome. Because males have only one X chromosome, they have only one copy of the ATP7A gene and so are severely affected by the disorder. Females have two X chromosomes. If they have a defective ATP7A gene, they are not severely affected, because their remaining X chromosome usually has a functioning ATP7A gene.

In their research, Dr. Kaler and his co-workers evaluated male infants who were considered to be at risk for Menkes disease.

Based on catecholamine levels, the researchers predicted 12 male newborns would develop Menkes disease and administered the copper-containing drug, beginning at a very early age. DNA studies of the ATP7A gene confirmed the diagnosis in each case. The infants were given the copper injections for three years, receiving two shots daily for the first year and one shot a day during the second and third years. Because long-term exposure to copper can damage the kidneys, the copper injections were stopped after 3 years. The researchers followed the infants throughout childhood to track their survival rates and mental development. Those who received injections soon after birth had a much greater survival rate when compared with a previously documented group of Menkes disease infants who had not received early copper injections.

Of the 12 males in the study, 92 percent were still alive an average of 4.6 years later. Only 13 percent of the males in the earlier group of late-diagnosed patients were alive an average of 1.8 years after diagnosis.

Dr. Kaler said that the study participants did not show any decline in health after stopping the copper replacement.

The boys varied in their response to the copper treatment. Two developed relatively normally, whereas the remainder had varying degrees of developmental impairment. When Dr. Kaler and his coworkers examined the nature of the defect in the boys' ATP7A gene, they found that boys with particular alterations in the gene responded better to the copper injections than did boys with other defects in the gene. They demonstrated that the ATP7A genes of the boys who had the best clinical responses to the copper injections retained some rudimentary capacity to regulate copper.

Dr. Kaler and his colleagues are now working to develop from their research a test that health care providers could use to routinely screen newborn males for Menkes disease.

"I think our findings may be especially meaningful to parents who have suffered due to this condition and lost children to it, Dr. Kaler said. "Menkes disease and other rare disorders of childhood convey a burden to families that is unfair and underappreciated. That a disorder occurs rarely is meaningless if one's child, grandchild, or sibling is affected."

Dr. Kaler added that while additional treatment approaches are still needed for many Menkes patients, the present work signals the beginning of an era when the parents of any infant born with this disease can anticipate better clinical outcomes. He encouraged couples with a family history of Menkes disease to contact the NIH if they have questions about this research study. He can be reached at 301 496-8368.

This work is described in the February 7 New England Journal of Medicine.


Story Source:

The above story is based on materials provided by NIH/National Institute of Child Health and Human Development. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute of Child Health and Human Development. "Fatal Copper Disorder Can Now Be Detected At Birth." ScienceDaily. ScienceDaily, 8 February 2008. <www.sciencedaily.com/releases/2008/02/080206203108.htm>.
NIH/National Institute of Child Health and Human Development. (2008, February 8). Fatal Copper Disorder Can Now Be Detected At Birth. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/02/080206203108.htm
NIH/National Institute of Child Health and Human Development. "Fatal Copper Disorder Can Now Be Detected At Birth." ScienceDaily. www.sciencedaily.com/releases/2008/02/080206203108.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins